Laurus Labs Ltd and PNB Housing Finance Ltd climbed up to 11 per cent in Friday's trade, following their September quarter results. While PNB Housing's net profit growth at 23 per cent beat Street ...

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, ...

Laurus Labs has seen a notable increase in its consensus analyst price target, which has risen from ₹724.14 to ₹815.86. This revision follows renewed analyst optimism, attributed largely to the ...

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Despite the broader market strength, Laurus Labs appears to be under pressure as CITI has maintained its ‘Sell’ rating with a ...

LAURUSLABS surged on June 1. The stock opened at Rs 334.65, up over 2 per cent from its Wednesday's close of Rs 330.7 on the ...

SUNNYVALE, Calif., May 30, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of ...

Laurus Labs has received a tentative nod from the Food and Drug Administration for Dolutegravir 5 mg and 10 mg for pediatric ARV treatment. This pediatric drug administration through oral dispersible ...

AI Quick Read Laurus Labs share price fell 3% in the trade on Friday after the company reported weak Q1 results impacted by lower sales, operational deleverage and elevated expenses. Laurus Labs ...

JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.